---
title: "Intra-Cellular Therap (ITCI.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ITCI.US.md"
symbol: "ITCI.US"
name: "Intra-Cellular Therap"
industry: "Pharmaceuticals"
---

# Intra-Cellular Therap (ITCI.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |

## Company Profile

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:14.000Z

**Overall: B (0.34)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 35 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 46.62% |  |
| Net Profit YoY | 46.54% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 680.85M |  |


**Multi Score**: B

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -8.58% | D |
| Profit Margin | -10.97% | D |
| Gross Margin | 56.95% | B |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 46.62% | A |
| Net Profit YoY | 46.54% | B |
| Total Assets YoY | 87.69% | A |
| Net Assets YoY | 94.19% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -911.74% | E |
| OCF YoY | 46.62% | A |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.65 | B |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 15.98% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Intra-Cellular Therap",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-8.58%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-10.97%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "56.95%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "46.62%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "46.54%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "87.69%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "94.19%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-911.74%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "46.62%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.65",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "15.98%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -187.76 | 236/257 | - | - | - |
| PB | 12.21 | 181/257 | 12.21 | 12.21 | 12.21 |
| PS (TTM) | 20.59 | 145/257 | 20.59 | 20.59 | 20.59 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 131.87 |

## References

- [Company Overview](https://longbridge.com/en/quote/ITCI.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ITCI.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ITCI.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
